$CLLS

Cellectis S.A.

Cellectis, headquartered in Paris, France, is a clinical-stage biotechnology company developing gene-edited cell and gene therapy product candidates. Its main product line is UCART, a portfolio of allogeneic CAR T-cell candidates designed as off-the-shelf treatments for cancers, initially focused on hematologic diseases including acute lymphoblastic leukemia and non-Hodgkin lymphoma. The company’s internally developed candidates include lasme-cel for B-cell acute lymphoblastic leukemia and eti-cel for B-cell non-Hodgkin lymphoma; it also has preclinical UCART programs for solid tumors. Cellectis uses its gene-editing technologies, including TALEN and PulseAgile electroporation, in its research and development programs. Cellectis develops candidates internally and licenses its technologies and product rights to other companies. Licensing relationships include agreements with AstraZeneca, Allogene, Servier and Iovance, covering development and commercialization rights or use of its gene-editing technology.

0
1
6

No SEC Form 4 filings for $CLLS in the last 30 days.

See all $CLLS insider activity →

Cellectis Reports Third-Quarter 2026 Results and In Vivo Editing Data

Cellectis SA reported Q3 2026 results with $149M in cash, $19.9M revenue (down from $67.4M), and increased R&D expenses to $108.8M. Preclinical data showed promising results for .HEAL-101 and .HEAL-201. The company is shifting focus to in vivo gene editing, discontinuing lasme-cel and eti-cel programs. Analysts rate CLLS stock as Buy with $8.00 target, while TipRanks' AI rates it Neutral.

CLLS sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 7 news stories mentioning CLLS (Cellectis S.A.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 6 bearish.

Recent CLLS coverage spans financial news, earnings and technology.

What's driving CLLS

  • Restructuring and pipeline reset likely increase near-term risk but extend cash runway into 2H 2028.

    european-biotechnology.com · Nov 17, 2026

  • The earnings miss and high cash burn suggest near-term downside, while the preclinical data may offer long-term upside if validated.

    tipranks.com · Nov 13, 2026

  • Cellectis reported 100.7 million shares and 105.6 million voting rights on Euronext Growth as of Oct. 31, according to a regulatory filing. The company provided contact details for media and investor relations.

    stocktitan.net · Nov 4, 2026

  • Cellectis (ALCLS) shared expanded preclinical data for its APOC3 base editor, .HEAL-101, and announced plans to initiate a Phase 1 investigator-initiated trial in China, with preliminary data expected in the second half of 2027.

    tradingview.com · Oct 27, 2026

  • Positive preclinical data may lift sentiment and drive near‑term buying interest ahead of the upcoming Phase‑1 trial.

    stocktitan.net · Oct 27, 2026

AlphAI scores every news story that mentions CLLS with an AI model for sentiment and relevance, and aggregates insider trades from Cellectis S.A.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CLLS

Score
$CLLSMedAI 8/10

Cellectis Reports Third-Quarter 2026 Results and In Vivo Editing Data

Cellectis SA reported Q3 2026 results with $149M in cash, $19.9M revenue (down from $67.4M), and increased R&D expenses to $108.8M. Preclinical data showed promising results for .HEAL-101 and .HEAL-201. The company is shifting focus to in vivo gene editing, discontinuing lasme-cel and eti-cel programs. Analysts rate CLLS stock as Buy with $8.00 target, while TipRanks' AI rates it Neutral.

Cellectis stock tumbles after Barclays double downgrade

Cellectis SA (CLLS) shares dropped 14.6% after Barclays downgraded the stock to Underweight, cutting its price target to $1.30 from $9.00. Analyst Lukas Shumway cited lack of conviction in Cellectis' new programs, assigning negative net present values to .HEAL-101 and .HEAL-201. The valuation model now includes $2 each for Royalties and Milestones, -$1 for Debt, and $5 for Cash, assuming a capital raise in late 2027.

Starbucks initiated, Expedia downgraded: Wall Street's top analyst calls

Analysts made several rating changes: Wolfe upgraded Paychex (PAYX) citing stable employment trends. UBS upgraded Union Pacific (UNP) to Buy with a $339 price target, expecting strong 2027 volume growth. Needham upgraded Rocket Pharmaceuticals (RCKT) to Buy with a $9 target after FDA reaffirmed study design. JPMorgan upgraded Credicorp (BAP) to Overweight with a $482 target, seeing strong EPS growth. Morgan Stanley downgraded Expedia (EXPE) to Underweight with a $235 target, citing weaker assets

This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Cellectis (NASDAQ:CL

Analysts downgraded several stocks: HSBC cut Banco Santander Brasil (BSBR) to Hold with a $6.2 target; Rosenblatt downgraded Ribbon Communications (RBBN) to Neutral with a $2.2 target; Citizens downgraded Cellectis (CLLS) to Market Perform; Barclays downgraded Scholar Rock (SRRK) to Equal-Weight with a $58 target; Raymond James downgraded Ascendis Pharma (ASND) to Outperform with a $287 target.

Related tickers